Answers are grounded in this paper and cite their sources.
Systematic review and meta-analysis assess the ROMA tool's efficacy in diagnosing ovarian cancer in women, indicating significant utility for risk stratification.
> .40). Fagan plots (anchored in GLOBOCAN-derived pre-test probabilities) showed ROMA's stratified clinical utility: positive results elevated post-test probability to 14 percent in postmenopausal women (a more notable uplift than 4 percent in the total population and 1 percent in premenopausal women), while negative results consistently ruled out ovarian cancer risk (post-test probability = 0) across all menopausal cohorts. ROMA is a reliable noninvasive tool for ovarian cancer diagnosis, with superior performance in postmenopausal women. Its value is enhanced in multi-modal workflows (e.g. with TVUS), supporting preoperative risk stratification. Identified heterogeneity highlights the need for standardized ROMA implementation.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: